Search DIAN Tissue Requests
Mariah S. Hahn
Targeting Dysregulated Synapse and Proteostasis Mechanisms in Alzheimer's Disease
06/03/2021
Develop a 3D culture system compatible with long-term (>3 month) iNeuron culture, extension, synapse formation and elimination, and quantitative assessment of neural circuit activity using “healthy” networks.
Compare AD_(PSEN1)-iNeuron cultures to iNeuron cultures derived from unaffected family member controls with respect to Aβ, tau phosphorylation, synapse maintenance and proteostasis.
Johannes Levin
Molecular detection of α-synuclein co-pathology in ADAD mutation carriers
04/29/2021
DIAN-T2104
Use real time quaking induced conversion (RT-QuIC) for ante mortem detection of Synuclein pathology in ADAD mutation carriers
Compare the data from RT-QuIC regarding in vivo detection of Synuclein pathology with data from post mortem examinations (manuscript in preparation).
Within the time frame of 15 years EYO we will analyse the time-point of emergence of LB pathology as measured by RT-QuIC .
We will analyse clinical and imaging data longitudinally comparing RT-QuIC positive and RT-QuIC negative participants.
Rawan Tarawneh
VE-cadherin in Alzheimer Disease
04/04/2021
Examine the diagnostic value of CSF and plasma levels of VE-cadherin as a marker of vascular injury in EOAD
Investigate whether VE-cadherin correlates with CSF and imaging measures of amyloid, tau, brain atrophy, and glucose hypometabolism in EOAD in cross-sectional and longitudinal analyses
Determine whether baseline VE-cadherin levels influences age of onset or rate of cognitive decline in asymptomatic and symptomatic mutation carriers
Oscar Harari
Metabolomic and lipidomics changes in ADAD
08/13/2020
Determine metabolite signatures of ADAD
Identify locus-metabolite and lipids associations via Metabolite genome-wide association studies (M-GWAS).
Charlotte Teunissen
Measurement of glial fibrillary acidic protein (GFAP) levels in blood for evaluation of astrocyte reaction in Alzheimer disease.
08/14/2020
Determine trajectory of GFAP over the ADAD disease course in relation to amyloid
Teunissen
Add-on DIAN project 3 Novel mechanisms: pilot OLINK proteomics in left-over CSF aliquots
08/14/2020
Study which OLINK proteins (signature) are discriminative between ADAD and controls
Compare with sporadi AD
Compare with Mass Spec in ADAD
Ronald Hawley
TEST BIO SUBMISSION
08/07/2020
test the form
test the form 2
test the form 3
test the form 4
Laura Ibanez
Plasma cell-free RNA as non-invasive biomarker for neurodegeneration
08/05/2020
Validate genomic models for disease pathology in Autosomal Dominant Alzheimer
Develop a specific predictive model for ADAD
Randall Bateman
Identification and validation of novel AD biomarkers for clinical development of Eisai AD pipelines
07/02/2020
To profile of CSF MTBR-tau isoforms which can be captured by E2814 across all DIAD stages using CSF samples from DIAN-observation cohort.
1) Dr. Alison M. Goate, 2) Dr. Sarah M. Neuner
Defining the role of microglia in Alzheimer’s disease risk and resilience
04/01/2020
Aim 1: Investigate the effect of high-risk or protective amyloid precursor protein (APP) mutations on microglia cell function.